Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


adhesion ( 41 / 23 /
5
/
13
)
Angiogenesis ( 244 / 127 /
34
/
83
)
Anoikis ( 22 / 12 /
4
/
6
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Apoptosis ( 1352 / 690 /
435
/
227
)
Autophagy ( 287 / 144 /
63
/
80
)
beta-catenin signaling ( 45 / 23 /
11
/
11
)
cell cycle ( 240 / 126 /
43
/
71
)
cell cycle arrest ( 483 / 245 /
210
/
28
)
Cell growth ( 640 / 324 /
88
/
228
)
Chemoresistance ( 254 / 128 /
44
/
82
)
colony formation ( 385 / 198 /
52
/
135
)
differentiation ( 95 / 48 /
31
/
16
)
DNA repair ( 47 / 24 /
16
/
7
)
EMT ( 623 / 318 /
129
/
176
)
growth ( 222 / 131 /
26
/
65
)
inflammation ( 51 / 26 /
7
/
18
)
Invasion ( 2717 / 1384 /
438
/
895
)
MET ( 16 / 9 /
7
/
)
Metastasis ( 867 / 442 /
170
/
255
)
migration ( 2169 / 1100 /
344
/
725
)
motility ( 155 / 80 /
23
/
52
)
NF-kB signaling ( 107 / 55 /
28
/
24
)
Oxaliplatin ( 2 / 1 /
1
/
)
Oxaliplatin resistance ( 23 / 12 /
5
/
6
)
Paclitaxel resistance ( 43 / 22 /
10
/
11
)
Proliferation ( 2990 / 1515 /
486
/
989
)
Radioresistance ( 83 / 43 /
15
/
25
)
Senescence ( 51 / 29 /
19
/
3
)
stemness ( 181 / 91 /
41
/
49
)
survival ( 132 / 68 /
23
/
41
)
Tamoxifen resistance ( 11 / 6 /
5
/
)
5fluorouracil resistance ( 70 / 44 /
11
/
15
)
AKT signaling ( 175 / 89 /
36
/
50
)
cell viability ( 222 / 115 /
30
/
77
)
cisplatin resistance ( 200 / 101 /
31
/
68
)
doxorubicin resistance ( 45 / 23 /
5
/
17
)
ERK pathway (MAPK pathway) ( 89 / 45 /
16
/
28
)
etoposide ( 7 / 4 /
2
/
1
)
Liver metastasis ( 22 / 13 /
3
/
6
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
multidrug resistance ( 20 / 11 /
4
/
5
)
RAS signaling pathway ( 8 / 5 /
1
/
2
)
tumor growth ( 571 / 288 /
96
/
187
)
cancer progression ( 16 / 9 /
5
/
2
)
cell cycle progression ( 159 / 81 /
40
/
38
)
Lung metastasis ( 39 / 21 /
6
/
12
)
PI3K signaling ( 73 / 37 /
12
/
24
)
WNT signaling ( 142 / 72 /
36
/
34
)
anchorage-independent growth ( 29 / 15 /
9
/
5
)
Castrate Resistance ( 21 / 13 /
7
/
1
)
Hedgehog (Hh) signaling ( 31 / 16 /
5
/
10
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
tumor-stroma interactions ( 3 / 2 /
1
/
)
Adriamycin (Adr) resistance ( 20 / 11 /
2
/
7
)
aerobic glycolysis ( 41 / 21 /
5
/
15
)
docetaxel resistance ( 23 / 13 /
6
/
4
)
epirubicin resistance ( 3 / 2 /
1
/
)
gefitinib resistance ( 22 / 12 /
2
/
8
)
JAK/STAT signaling ( 82 / 42 /
22
/
18
)
mTOR signaling ( 72 / 36 /
8
/
28
)
NOTCH signaling ( 51 / 26 /
15
/
10
)
P38 signaling ( 29 / 15 /
10
/
4
)
poor prognosis ( 46 / 26 /
17
/
3
)
Transformation ( 15 / 12 /
2
/
1
)
tumor progression ( 82 / 42 /
24
/
16
)
Tumorigenesis ( 39 / 20 /
6
/
13
)
Vorinostat Resistance ( 6 / 4 /
2
/
)
cytotoxicity ( 2 / 1 /
1
/
)
TGF-beta signaling ( 354 / 200 /
78
/
76
)
Temozolomide (TMZ) resistance ( 24 / 12 /
5
/
7
)
BMP signaling ( 108 / 63 /
13
/
32
)
daunorubicin (DNR) Resistance ( 4 / 2 /
2
/
)
T cell activation ( 3 / 2 /
1
/
)
gemcitabine resistance ( 30 / 15 /
4
/
11
)
genomic instability ( 2 / 1 /
1
/
)
Sorafenib resistance ( 26 / 13 /
6
/
7
)
glucose metabolism ( 14 / 7 /
3
/
4
)
BRCAness ( 2 / 1 /
1
/
)
immunoevasion ( 16 / 8 /
3
/
5
)
Hippo signaling pathway ( 164 / 82 /
65
/
17
)
fibrosis ( 8 / 4 /
2
/
2
)
MAPK/JNK Signaling Pathway ( 8 / 4 /
4
/
)
Hypoxic response ( 8 / 5 /
3
/
)
tumor-initiating properties ( 9 / 6 /
/
3
)
ER stress ( 28 / 15 /
/
13
)
cell spreading ( 8 / 6 /
/
2
)
inflammatory monocyte recruitment ( 4 / 3 /
/
1
)
Bone metastasis ( 12 / 8 /
/
4
)
Imatinib resistance ( 6 / 5 /
/
1
)
NK cell cytotoxicity ( 6 / 4 /
/
2
)
Camptothecin resistance ( 3 / 2 /
/
1
)
disease-free survival ( 3 / 2 /
/
1
)
MTX resistance ( 3 / 2 /
/
1
)
Osteolysis ( 5 / 3 /
/
2
)
unfolded protein response ( 5 / 4 /
/
1
)
gluconeogenesis ( 4 / 2 /
/
2
)
lipogenesis ( 23 / 12 /
/
11
)
Afatinib resistance ( 2 / 1 /
/
1
)
Lapatinib resistance ( 2 / 1 /
/
1
)
Neratinib resistance ( 2 / 1 /
/
1
)
Brain metastasis ( 2 / 1 /
/
1
)
BRAFi resistance ( 2 / 1 /
/
1
)
MEKi resistance ( 2 / 1 /
/
1
)
carboplatin resistance ( 2 / 1 /
/
1
)
Taxanes (paclitaxel and docetaxel) resistance ( 8 / 7 /
/
1
)
Trastuzumab resistance ( 2 / 1 /
/
1
)
TRAIL resistance ( 2 / 1 /
/
1
)
Rapamycin resistance ( 2 / 1 /
/
1
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
cell polarity ( 1 / 1 /
0
/
0
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
chondrogenesis ( 1 / 1 /
0
/
0
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)
EGFR-TKI resistance ( 2 / 2 /
0
/
0
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
erythropoiesis ( 3 / 3 /
0
/
0
)
glycolysis ( 10 / 10 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
insulin signaling ( 1 / 1 /
0
/
0
)
macrophage attraction ( 1 / 1 /
0
/
0
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)
recurrence ( 2 / 2 /
0
/
0
)
redox homeostasis ( 3 / 3 /
0
/
0
)
Response to oxidative stress ( 5 / 5 /
0
/
0
)
Response to genotoxic stress ( 2 / 2 /
0
/
0
)
scattering ( 1 / 1 /
0
/
0
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)